Precious Cargo: The Role of Polymeric Nanoparticles in the Delivery of Covalent Drugs

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2024 Oct 26

PMID 39459317

Authors

Daniel Weissberger

Martina H Stenzel

Luke Hunter

Affiliations

Soon will be listed here.

Abstract

Covalent drugs can offer significant advantages over non-covalent drugs in terms of pharmacodynamics (i.e., target-binding properties). However, the development of covalent drugs is sometimes hampered by pharmacokinetic limitations (e.g., low bioavailability, rapid metabolism and toxicity due to off-target binding). Polymeric nanoparticles offer a potential solution to these limitations. Delivering covalent drugs via polymeric nanoparticles provides myriad benefits in terms of drug solubility, permeability, lifetime, selectivity, controlled release and the opportunity for synergistic administration alongside other drugs. In this short review, we examine each of these benefits in turn, illustrated through multiple case studies.

References

Gandhi V, Burger J . Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block. Clin Cancer Res. 2009; 15(24):7456-7461. PMC: 2795094. DOI: 10.1158/1078-0432.CCR-08-3041. View

Ghosh A, Samanta I, Mondal A, Liu W . Covalent Inhibition in Drug Discovery. ChemMedChem. 2019; 14(9):889-906. PMC: 6816337. DOI: 10.1002/cmdc.201900107. View

Yang Y, Huang Z, Li J, Mo Z, Huang Y, Ma C . PLGA Porous Microspheres Dry Powders for Codelivery of Afatinib-Loaded Solid Lipid Nanoparticles and Paclitaxel: Novel Therapy for EGFR Tyrosine Kinase Inhibitors Resistant Nonsmall Cell Lung Cancer. Adv Healthc Mater. 2019; 8(23):e1900965. DOI: 10.1002/adhm.201900965. View

Liebler D, Guengerich F . Elucidating mechanisms of drug-induced toxicity. Nat Rev Drug Discov. 2005; 4(5):410-20. DOI: 10.1038/nrd1720. View

Chithrani B, Ghazani A, Chan W . Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 2006; 6(4):662-8. DOI: 10.1021/nl052396o. View

Uetrecht J, Naisbitt D . Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev. 2013; 65(2):779-808. PMC: 3639727. DOI: 10.1124/pr.113.007450. View

Rangaraj N, Pailla S, Chowta P, Sampathi S . Fabrication of Ibrutinib Nanosuspension by Quality by Design Approach: Intended for Enhanced Oral Bioavailability and Diminished Fast Fed Variability. AAPS PharmSciTech. 2019; 20(8):326. DOI: 10.1208/s12249-019-1524-7. View

Qian L, Zheng J, Wang K, Tang Y, Zhang X, Zhang H . Cationic core-shell nanoparticles with carmustine contained within O⁶-benzylguanine shell for glioma therapy. Biomaterials. 2013; 34(35):8968-78. DOI: 10.1016/j.biomaterials.2013.07.097. View

Zhao L, Tang B, Tang P, Sun Q, Suo Z, Zhang M . Chitosan/Sulfobutylether-β-Cyclodextrin Nanoparticles for Ibrutinib Delivery: A Potential Nanoformulation of Novel Kinase Inhibitor. J Pharm Sci. 2019; 109(2):1136-1144. DOI: 10.1016/j.xphs.2019.10.007. View

10.

Li Y, Wu H, Yang X, Jia M, Li Y, Huang Y . Mitomycin C-soybean phosphatidylcholine complex-loaded self-assembled PEG-lipid-PLA hybrid nanoparticles for targeted drug delivery and dual-controlled drug release. Mol Pharm. 2014; 11(8):2915-27. DOI: 10.1021/mp500254j. View

11.

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

12.

Morton S, Lee M, Deng Z, Dreaden E, Siouve E, Shopsowitz K . A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. Sci Signal. 2014; 7(325):ra44. PMC: 4138219. DOI: 10.1126/scisignal.2005261. View

13.

Zhou X, Chang T, Chen S, Liu T, Wang H, Liang J . Polydopamine-Decorated Orlistat-Loaded Hollow Capsules with an Enhanced Cytotoxicity against Cancer Cell Lines. Mol Pharm. 2019; 16(6):2511-2521. DOI: 10.1021/acs.molpharmaceut.9b00116. View

14.

Wang Y, Pi C, Feng X, Hou Y, Zhao L, Wei Y . The Influence of Nanoparticle Properties on Oral Bioavailability of Drugs. Int J Nanomedicine. 2020; 15:6295-6310. PMC: 7455773. DOI: 10.2147/IJN.S257269. View

15.

Singh J . The Ascension of Targeted Covalent Inhibitors. J Med Chem. 2022; 65(8):5886-5901. DOI: 10.1021/acs.jmedchem.1c02134. View

16.

Potashman M, Duggan M . Covalent modifiers: an orthogonal approach to drug design. J Med Chem. 2009; 52(5):1231-46. DOI: 10.1021/jm8008597. View

17.

Khalil S, El-Feky G, El-Banna S, Khalil W . Preparation and evaluation of warfarin-β-cyclodextrin loaded chitosan nanoparticles for transdermal delivery. Carbohydr Polym. 2012; 90(3):1244-53. DOI: 10.1016/j.carbpol.2012.06.056. View

18.

Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y . Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. Front Mol Biosci. 2020; 7:193. PMC: 7468194. DOI: 10.3389/fmolb.2020.00193. View

19.

Patra J, Das G, Fraceto L, Campos E, Del Pilar Rodriguez-Torres M, Acosta-Torres L . Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018; 16(1):71. PMC: 6145203. DOI: 10.1186/s12951-018-0392-8. View

20.

Kim D, Kim J, Kim R, Maharjan P, Ji Y, Jang D . Orlistat-loaded solid SNEDDS for the enhanced solubility, dissolution, and in vivo performance. Int J Nanomedicine. 2018; 13:7095-7106. PMC: 6223334. DOI: 10.2147/IJN.S181175. View